Fundraising Fox

Galecto Biotech

8 known investors

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.

BiotechMedical Devices

Founders & leadership

JJJennifer Jarrett
Jennifer JarrettinChief Executive Officer & Board DirectorChief Executive Officer & Board Director at Damoratx
SSSherwin Sattarzadeh
Sherwin SattarzadehinChief Operating OfficerChief Operating Officer at Damoratx
BHBecker Hewes
Becker HewesChief Medical Officer
GWGarrett Winslow
Garrett WinslowinGeneral Counsel
JBJim Baker
Jim BakerinChief Corporate Affairs Officer
BBBrian Burkavage
Brian BurkavageinSenior Vice President, Finance

Investors · 8

EIR VenturesStockholm
Hadean VenturesOslo
M VenturesLos Angeles · $10.8M
SEED Capital DenmarkCopenhagen · $2.1M – $4.3M
Sunstone CapitalFrederiksberg
Ysios CapitalBarcelona · $5.4M – $21.6M
Maverick VenturesreportedSan Francisco · $3M – $10M
OrbiMedreportedNew York · $1M – $75M

In the news

Primary Myelofibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotechbarchart.com · Apr 2026Novo-backed Galecto Biotech scores €79 million in Series C fundingendpoints.news · Oct 2018Galecto raises €79M to run late-phase IPF trial | Fierce Biotechfiercebiotech.com · Oct 2018Galecto Biotech Raises €79M in Series C Financing - FinSMEsfinsmes.com · Oct 2018

Frequently asked questions

What does Galecto Biotech do?
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.
Who are Galecto Biotech's investors?
Galecto Biotech's investors include EIR Ventures, Hadean Ventures, M Ventures, SEED Capital Denmark, Sunstone Capital, Ysios Capital, Maverick Ventures, OrbiMed.